Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRCT-101SR in pediatric ADHD
NCT06215144Phase 3Terminated
- Sponsor
- Neurocentria Inc.
- Start
- Jan 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of NRCT-101SR in attention deficit hyperactivity disorder (ADHD), sponsored by Neurocentria Inc.. Started Jan 2024; status: terminated.
02
Drugs
NRCT-101SR
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT06215144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06215144.